Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | KLK3 | P07288 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796604 | 0.83 | KMT2A (0.49) | MAPTSMN1; SMN2PLAUKDM4EMEN1 | |
| SCHEMBL5318975 | 0.83 | MAPT (0.66) | MAPTSMN1; SMN2PLAUKDM4EGAA | |
| SCHEMBL4798133 | 0.82 | MAPT (0.64) | MAPTSMN1; SMN2PLAUKDM4EMEN1 | |
| SCHEMBL4795125 | 0.80 | GRM4 (0.50) | MAPTSMN1; SMN2PLAUKDM4EMEN1 | |
| SCHEMBL4796659 | 0.80 | KDM4E (0.49) | MAPTSMN1; SMN2KDM4EGAAMEN1 | |
| SCHEMBL4797954 | 0.79 | KDM4E (0.47) | MAPTSMN1; SMN2KDM4EGAAMEN1 | |
| SCHEMBL28286591 | 0.78 | MAPT (0.60) | MAPTSMN1; SMN2PLAUKDM4EMEN1 | |
| SCHEMBL28502195 | 0.78 | MAPT (0.43) | MAPTSMN1; SMN2PLAUKDM4EGAA | |
| SCHEMBL4798226 | 0.78 | MAPT (0.43) | MAPTSMN1; SMN2KDM4EGAAIMPDH2 | |
| SCHEMBL30354884 | 0.77 | MAPT (0.53) | MAPTKDM4EGAAIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | claimed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | claimed |
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | disclosed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | MAPT 4429/4885SMN1; SMN2 1107/4885PLAU 4128/4885 |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | MAPT 4353/4885SMN1; SMN2 915/4885PLAU 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.